Atropos Health Pitch Deck: All 22 Slides + Teardown

Atropos Health's 22-slide Series B deck is a sophisticated example of how to transition deep academic research into a commercial powerhouse. By highlighting a decade of innovation at Stanford University (Slide 4) and a federated network covering over 200 million patients (Slide 10), the company establishes immediate authority in the high-stakes healthcare sector. The deck effectively categorizes its product suite under the 'Geneva OS' umbrella, showcasing a clear path from raw data to actionable clinical insights in under three minutes via their ChatRWD interface (Slide 7). While the deck is…

Key takeaways

• The company leverages a 'decade of medical innovation' starting from the Shah Lab in 2011 to establish deep technical defensibility (Slide 4).
• Atropos claims a federated network of over 200 million patients across dozens of datasets, providing significant data gravity (Slide 10).
• The product architecture, Geneva OS, supports multiple 'live' modules including ChatRWD, Alexandria, and Workbench (Slide 7).
• The business model is a user-based SaaS structure with four distinct upsell levers: user growth, data set deployment, evidence network usage, and new product access (Slide 13).
• A Net Promoter Score (NPS) of >40 is cited as a key indicator of user satisfaction and speed to value (Slide 10).
• The deck includes a specific ROI case study claiming over $3M in institutional savings for a hospital partner (Slide 21).
• Competitive positioning focuses on the 'evidence gap,' contrasting Atropos's personalized content against static reference materials like PubMed (Slide 16).
• The deck omits a dedicated team slide, though it references founder Dr. Nigam Shah's work at Stanford (Slide 4).

Frequently asked questions

What is the core technology behind Atropos Health?

The core technology is Geneva OS, which acts as a data-to-evidence conversion pipeline. It includes ChatRWD, a generative AI interface that allows users to query real-world evidence (RWE) and receive answers in under three minutes. This system is built on a decade of research from Stanford University, specifically the 'Green Button' project, which aims to provide clinicians with instant, data-driven insights at the point of care.

How does Atropos Health make money?

Atropos utilizes a user-based SaaS model. Revenue is generated through base license fees per user bundle. Growth is driven by four primary upsell mechanisms: increasing the number of users within an account, charging for each new dataset deployed at a client site, fees for accessing the Atropos Evidence Network, and SKU growth through new product launches like their Alexandria library or CRAFT tool.

Who are the primary customers for Atropos Health?

The deck identifies two main customer segments: Healthcare Providers/Academic Medical Centers (AMCs) and Life Sciences companies. For providers, the value proposition is clinical decision support and hospital cost savings. For life sciences, the platform accelerates research initiatives, clinical trial emulation, and drug development by providing rapid access to high-quality real-world evidence.

How does Atropos differentiate itself from competitors like PubMed or UpToDate?

Atropos argues that existing solutions like PubMed or UpToDate rely on 'static content' that lacks personalization for specific patient cohorts. In contrast, Atropos generates 'new high-quality personalized content' by analyzing real-time patient data. They position themselves as the only resource that answers clinical questions by creating evidence rather than just searching for existing literature.

What evidence of market traction does the deck provide?

Traction is demonstrated through a mix of data scale (200M+ patients), user satisfaction (NPS >40), and institutional validation. The deck cites partnerships with Mayo Clinic and AWS, publications in journals like JAMA and The New England Journal of Medicine, and a specific case study where a hospital saved over $3M using their platform.

Atropos Health pitch deck: the facts

Company

Atropos Health

Year

2024

Stage

Series B

Slides

22

Sector

Healthcare Technology / AI

Deck type

Investor Presentation

Outcome

$33M Raised

Headquarters

North America

Atropos Health pitch deck PDF

The full Atropos Health deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Atropos Health pitch deck was used for

This is Atropos Health’s 2024 **Series B** pitch deck, used to raise $33M to scale its ‘Green Button’ and Geneva OS platform that converts siloed healthcare data into actionable, publication-grade real‑world evidence in minutes.[1][3][10] The deck positions Atropos as a pioneer in real‑world evidence and value‑based care, emphasizing its Atropos Evidence Network, Alexandria™ evidence library, and the LLM-based ChatRWD interface originally developed at Stanford.[1][3][6][10] The funds from this Series B, led by Valtruis with strategic investors such as Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, were earmarked to expand the Evidence Network, invest in generative AI applications, and grow vertical integrations (e.g., oncology).[1][2][11] The teardown focuses on how Atropos balanced academic rigor (peer‑reviewed methodologies and published literature) with a scalable SaaS and data network business model targeting value-based care and life sciences customers, as reflected in the traction and product slides provided.[1][3][6][10]

Business model: Healthcare technology company providing a clinical analytics and generative AI platform that converts real-world clinical data into high-quality, personalized real-world evidence for providers, health systems, and life sciences organizations.[1][10][12]

Round

Series B (early stage VC, generating revenue).[1][8]

Lead investor

Valtruis[1][2][3][11]

Investors

Valtruis (lead investor)[1][2][3][11], Cencora Ventures[1][2][3][5][11], McKesson Ventures[1][2][3][5][11], Merck Global Health Innovation Fund (Merck GHI Fund)[1][2][3][5][11], Breyer Capital[1][2][3][5][11][14], Emerson Collective[1][2][3][5][11][14], Presidio Ventures (Sumitomo Corporation Venture Group)[1][2][3][5][11][13]

Founded

2019[4][6]

Founders

Nigam Shah[4][7], Brigham Hyde[4][7], Saurabh Gombar[4][7]

Headquarters

New York City, New York, United States[6][12][15]

Year: 2024[1][2][3][8][11]

Raising: Series B growth capital to expand the Atropos Evidence Network, invest in generative AI applications (ChatRWD), and support value-based care decision-making and vertical integrations such as oncology.[1][11][12]

Raised: $33M Series B funding round completed in May 2024.[1][2][3][8][11]

Industry: Healthcare Technology / AI-driven clinical analytics and real-world evidence generation[1][10][12][15]

Total funding: Approximately $47M–$50M total disclosed funding, including a $14M Series A and a $33M Series B.[6][9][14]

Use of funds as presented: Invest in real-world evidence for value-based care decision-making, grow the Atropos Evidence Network (including vertical integrations like oncology and specialty areas), and expand investment in generative AI applications such as ChatRWD.[1][11][12]

What happened after the Atropos Health deck

As of after its May 2024 Series B, Atropos Health is an active healthcare technology company that has raised at least $47M–$50M in disclosed funding, operates a large federated evidence network with hundreds of millions of de‑identified patient records, and offers Geneva OS, ChatRWD, and the Alexandria™ Evidence Library to generate high‑quality real‑world evidence for clinical and commercial decis

• Completed a $14M Series A round in 2022 led by Breyer Capital with participation from Emerson Collective and Boston Mill
• Completed a $33M Series B round in May 2024, led by Valtruis with participation from Cencora Ventures, McKesson Ventures
• Built an Atropos Evidence Network covering over 200M de‑identified patients across dozens of datasets, positioning the c
• Developed the Alexandria™ Evidence Library with more than 10,000 pre‑built real‑world data studies spanning specialties
• Launched Geneva OS and the generative AI application ChatRWD to enable chat‑based access to real‑world data and evidence

What the Atropos Health deck got right

• Compelling mission and strategic framing of evidence as currency. Clear mission and framing—"accelerate the generation of actionable evidence to improve healthcare outcomes for everyone" and positioning evidence as the "currency of value in healthcare"—creates a strong conceptual anchor that ties the product directly to value-based care, formulary decisions, and shared decision‑making.[Slide 2][Slide 5]
• Demonstrated speed to evidence and strong user satisfaction. The deck highlights dramatic improvements in speed and usability: Atropos converts siloed healthcare data into publication‑grade evidence "from months down to minutes" and reports 24‑hour average study completion and <3‑minute runs via ChatRWD, supported by an NPS of 42 versus an industry average of 10–15.[Slide 6][Slide 10][Slide 11]
• Large, rerunnable study library enabling day‑one ROI. Alexandria™ Evidence Library offers 10,000+ pre‑built real‑world data studies across specialties and therapeutic areas that can be unlocked on day one and re‑run on the Atropos Evidence Network, providing immediate, rerunnable, ROI‑generating content and a powerful content flywheel.[Slide 9]
• Scaled federated data network with 200M+ de‑identified patients. The Atropos Evidence Network already covers 200M de‑identified patients across dozens of datasets, with a stated path to global coverage, giving Atropos scale and defensibility in its data assets and supporting personalized medicine and research across diverse cohorts.[Slide 10][Slide 11]
• Strong focus on methodological rigor, transparency, and quality. The deck emphasizes methodological rigor—"backed by a decade of published literature and development," "highly published methodologies," and a 100% peer‑review success rate—combined with transparency, audit capabilities, and data quality scoring, which is crucial for investor confidence in a clinical AI product.[Slide 6][Slide 10]
• Differentiated generative AI interface (ChatRWD) built on validated methods. User experience differentiation via a newly launched LLM-based interface (ChatRWD), originally developed at Stanford, positions Atropos at the intersection of generative AI and clinical informatics, offering a conversational way to access real‑world evidence while leveraging validated methodologies.[Slide 10]

What could have been stronger

• Limited quantified clinical and economic outcomes. The deck emphasizes "10K+ studies completed" and "publication grade" evidence but, in the provided slides, does not show concrete clinical outcome improvements (e.g., reduced readmissions, cost savings, or specific value‑based care KPIs) tied directly to those studies, which limits the ability to assess impact beyond process speed.[Slide 6][Slide 9][Slide 11]
• Scientific validation not easily verifiable from slides. Although the deck mentions being backed by a decade of published literature and a 100% peer‑review success rate, it does not list specific flagship publications, journals, or example studies in the excerpted slides, making it harder for investors to quickly verify scientific validity from the deck alone.[Slide 6][Slide 10]
• Data network composition not clearly broken out. The pitch highlights 200M de‑identified patients and a path to the "largest federated network" but does not, in the visible slides, break down data sources (e.g., number of health systems, payers, or geographies), which may leave questions about data diversity and representativeness.[Slide 10][Slide 11]
• Economic value story is asserted more than demonstrated. The deck claims very high speed (24 hours to study completion, <3 minutes with ChatRWD) and high NPS scores, but the provided slides do not show pricing, unit economics, or concrete examples of customer ROI beyond saying day‑one ROI, which can make the business case less tangible.[Slide 6][Slide 9][Slide 11]
• Broad positioning across many use cases without clear GTM focus. Atropos positions itself in multiple segments (value‑based care, formulary decisions, drug discovery, personalized medicine), but the excerpted slides do not clearly prioritize a primary beachhead segment or go-to-market focus, which may raise questions about focus and sales motion.[Slide 5][Slide 6][Slide 9]

How an investor would read this deck

What draws attention

• Demonstrated ability to convert siloed health data into publication‑grade evidence with automation, reducing time from months to minutes and enabling large libraries of rerunnable studies that generate day‑one ROI.[Slide 6][Slide 9][Slide 11]
• Scale and uniqueness of the Atropos Evidence Network, with 200M+ de‑identified patients and a trajectory toward the largest federated network of healthcare data, which underpins defensibility and value to life sciences and value‑based care stakeholders.[Slide 10][Slide 11][1][6]
• Differentiated Alexandria™ evidence library with 10,000+ pre‑built studies across clinical specialties and therapeutic areas, enabling instant use at install and driving ROI and data network flywheel dynamics.[Slide 9][1]
• Strong founder and leadership credentials, including ties to Stanford, and highly published methodologies with a claimed 100% peer‑review success rate, mitigating scientific risk for an AI‑driven clinical product.[1][6][7][10]
• Series B validation by healthcare- and value‑based care‑oriented investors such as Valtruis, Cencora Ventures, McKesson Ventures, Merck GHI Fund, Breyer Capital, Emerson Collective, and Presidio Ventures, indicating strategic alignment and market credibility.[1][2][3][5][11]

Risks that stand out

• Regulatory and clinical risk associated with using AI‑generated or automated real‑world evidence in clinical decision support and value‑based care contracts, particularly as regulators scrutinize AI in healthcare and as evidence standards evolve.[12][13]
• Dependence on access to large-scale, high‑quality healthcare datasets; changes in data‑sharing policies, privacy regulations, or key data partnerships could impact the Atropos Evidence Network’s coverage and value.[10][12]
• Execution risk in scaling a complex product stack (Geneva OS, ChatRWD, Alexandria, Evidence Network) across multiple segments (providers, payers, life sciences) without diluting focus or overextending go‑to‑market resources.[6][9][10][15]
• Competitive risk from other clinical analytics, RWE, and AI decision support platforms that may also build federated networks and generative interfaces, potentially compressing margins or commoditizing evidence generation over time.[6][10][15]
• Scientific and reputational risk if the claimed 100% peer‑review success rate or "publication-grade" evidence standard is challenged by negative outcomes, conflicting studies, or if customers misuse evidence outputs in ways that lead to poor clinical results.[Slide 6][Slide 10]

Questions this deck invites

• Can Atropos provide specific case studies where its evidence generation measurably improved clinical outcomes or financial performance (e.g., reduced readmissions, drug spend optimization, value‑based contract performance), and how often ar
• What is the detailed composition of the Atropos Evidence Network (types of data sources, number of health systems and payers, geographic spread), and how does Atropos ensure data diversity, representativeness, and ongoing access given evolv
• How does Atropos price Geneva OS, ChatRWD, and Alexandria (subscription vs. usage-based), what are gross margins and payback periods, and how do customers typically realize the claimed day‑one ROI from rerunnable studies?[Slide 6][Slide 9][
• What governance, validation, and guardrails are in place for the LLM-based ChatRWD experience to prevent hallucinations or clinically unsafe outputs, and how is responsibility allocated between Atropos and provider organizations when the to
• What is Atropos’s go-to-market focus (e.g., health systems vs. payers vs. pharma) over the next 2–3 years, and how does the company plan to scale sales and customer success while maintaining high NPS and scientific rigor at larger scale?[Sl

What founders can take from the Atropos Health deck

• Anchoring a healthcare AI pitch deck around a clear mission statement—accelerating actionable evidence for better outcomes—helps investors quickly connect the product to system‑level challenges (evidence gaps, value‑based care pressures).
• Showing concrete speed and usability metrics (e.g., 24‑hour study completion, <3‑minute ChatRWD runs, and NPS 42 vs. an industry average of 10–15) makes abstract AI and analytics value more tangible to investors.
• Including a large, pre‑built content library (10K+ rerunnable studies) in the deck demonstrates immediate ROI and reduces perceived adoption friction, which can be compelling for health system and pharma buyers who fear long implementations.
• Positioning evidence as the "currency of value in healthcare" reframes the product from a point solution into an infrastructure layer for value‑based care, formulary decisions, and research, which can justify a network- and platform‑oriented valuation.
• Highlighting a sizable federated data network (200M de‑identified patients) alongside published methodologies and peer‑review success builds both scale and credibility—a useful template for other data‑network pitches in regulated industries.
• Clarifying the role of generative AI (ChatRWD) as a user interface on top of validated methodologies, rather than as a standalone black box, can reduce investor concern about AI safety while still showcasing innovation and differentiation.

Atropos Health pitch deck: common questions

What does Atropos Health do, in practical terms?

Atropos Health is a healthcare technology company that turns real-world clinical data into high-quality, personalized real‑world evidence for physicians, health systems, and life sciences organizations to improve decision-making and outcomes.[1][10][12] Its platform installs on existing medical data (e.g., EHRs, claims, registries), structures it for downstream use, and then uses automation and generative AI to answer specific clinical and commercial questions in minutes rather than months.[6][10][15]

How much did Atropos Health raise in its Series B, and who invested?

In May 2024, Atropos Health completed a **$33M Series B** funding round.[1][2][3][8] The round was led by **Valtruis**, with participation from new strategic investors **Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund**, alongside existing investors **Breyer Capital, Emerson Collective, and Presidio Ventures**.[1][2][3][5][11] The capital was earmarked to expand the Atropos Evidence Network, invest in the generative AI application ChatRWD, and deepen support for value‑based care use cases.[1][11][12]

What is Atropos Health’s mission and core value proposition in this Series B deck?

The deck describes Atropos Health’s mission as "to accelerate the generation of actionable evidence to improve healthcare outcomes for everyone," and it situates the company in "the Question & Evidence Business," framing **evidence as the currency of value in healthcare**.[Slide 2][Slide 5] It highlights the ability to convert siloed healthcare data into publication‑grade evidence in minutes, backed by a decade of published methodology and transparency for every analysis.[Slide 6]

What traction and product metrics does the deck highlight?

According to the traction and product slides, Atropos reported **10K+ studies completed**, a **content library of rerunnable studies** that can generate day‑one ROI, **200M de‑identified patients** on the Evidence Network, an **NPS of 42** versus a healthtech average of 10–15, and an **average time to study completion of 24 hours**, with ChatRWD reducing this to less than 3 minutes.[Slide 9][Slide 10][Slide 11] External profiles and the company site corroborate that Atropos operates one of the largest federated networks of healthcare data, serving healthcare providers and life sciences customers.[1][6][10][12]

Which pitch deck is this, and what was Atropos Health raising for?

The deck shown by Business Insider is the **Series B fundraising deck** used in 2024 to support the $33M round.[3] It emphasizes scaling the Atropos Evidence Network, monetizing Alexandria’s 10,000+ pre‑built studies for immediate ROI, and investing in the LLM‑based user interface ChatRWD.[Slide 6][Slide 9][Slide 10][Slide 11] The company’s official Series B announcement confirms these use-of-funds priorities and the focus on value‑based care decision‑making.[1][11]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Atropos Health Announces $33M Series B
• AI clinical decision support firm Atropos Health raises $33M
• Pitch Deck That Got Atropos Health $33 Million for Its Generative AI
• Atropos Health — Investors & Founders | Fundraising Fox
• How Atropos Health Launched the World's Largest Medical ...
• Atropos Health
• About Us - Atropos Health
• Atropos Health 2025 Company Profile: Valuation, Funding & Investors | PitchBook

Atropos Health pitch deck slides

What each slide of the Atropos Health pitch deck says

Slide 2

Our Mission To accelerate the generation of actionable evidence to improve healthcare outcomes for everyone. ATROPOSHEALTH Confidential & Proprietary 2

Slide 3

. . Med Ica | decisions are o Only 14% of daily medical decisions are backed by high . quality evidence?, this is known as “The Evidence Gap’ not routinely made . . Clinical trials are too few, and those that are run based [eo] n h igh -q u a | ity 2] systematically exclude 70% of patients . (those with comorbidities) as well as underrepresented evidence. groups (minorities, elderly, children, intl, etc.) (5) Healthcare data is now plentiful, if siloed, but Pie. converting it to high quality evidence takes months and 14% Traditional approaches to is resource intensive, limiting it to expensive research 2 medical decisions are rarely | Utllize backed by evidence, this is k sethings 4 acked b…

Slide 4

Atropos Health Represents a Decade of Medical Innovation = @ ue B sien Health Affairs 8 miss 4 Dr. Nigam Shah on the Informatics Consult J /\ NM | /\ npj | digital fedicing 7) Stanford os cual speed ge HEALTH CARE Atropos inthe News £°) ATROPOSHEALTH @ maize HOSPITAL REVIEW sca = clinical informatics technology. i £3 ATROPOSHEALTH Confidential & Proprietary 4

Slide 5

ATROPOS SOLUTION Atropos is in the Question & Evidence Business, Creating the Trusted Currency of Valuein HC Formulary & Medical FDA Benefit Position Evidence Is the Currency of Value in Healthcare ACO & VBC Out-of-Pocket Contracts Cost & Co-Pay — ¥ S Access & Research Coverage Collaboratives Decisions Lfi'iz:it?'g Shared Decision Making System Personalized Medicine £ ATROPOSHEALTH Confidential & Proprietary 5

Slide 6

ATROPOS SOLUTION Atropos Converts Siloed HC Data into High Quality Evidence in Minutes S288 # Speed to Evidence and Insight # From months down to minutes to produce high quality publication grade evidence # High Quality, Transparency, Accuracy and Best in # Breed Methodology Backed by a decade of published literature and development, Atropos provides transparency and quality for every analysis £'y ATROPOSHEALTH Prognostogram Report Insights Reccommended Actions Access to Scalar Federated Data Through the Atropos Evidence™ Network users can access hundreds of millions of patient records for analysis Scalar Content that is ROl Generating Day 1 With a library of thousands of existing studies,…

Slide 9

PRODUCT INNOVATION Unlock Thousands of Studies on Day One with Alexandria™ Evidence Library Alexandria includes 10,000+ novel RWD studies that span clinical specialties, therapeutic areas, and cohorts. You can search, browse, and access critical knowledge upon install - and also re-run these pre-programmed studies on RWD in the Atropos Evidence Network to generate new RWE. Leverage Alexandria to: ksl o T ool Fiogsaiingrrn v Provide physicians better treatment options based on the evidence by running studies on larger, more inclusive data sets Aoy L g v Access real-time, real-world data and evidence to Cordalogy 27) Tassarch736) accelerate drug discovery on traditionally [——— . - underrepres…

Slide 10

What makes Atropos Health unique? User Experience and Speed to Value through Automation Unmatched speed, user NPS >40, proprietary tech originally developed at Stanford University. Newly launched LLM-based user experience: ChatRWD. £'y ATROPOSHEALTH Path to Largest Federated Network of Healthcare Data Over 200M patients across dozens of datasets already, with line of sight on global coverage. Quality, Transparency, Accuracy and Scalar Training Content for LLMs Highly published methodologies, 100% peer-review success rate, data quality and fitness scoring, audit capabilities, and rerunnable scalar study content native to platform. Confidential & Proprietary 10

Slide 11

10K+ Studies Completed Growing content library of rerunnable studies that can generate day 1 ROI Traction and Growth 200M De-ID Patients on Evidence Network Onapath to becoming the largest federated network of healthcare data 42 Net Promoter Score Compared to a healthtech industry average of 10-15. Users love our products. 24hrs Average Time to Study Completion Versus months to complete in current standards. CHATRWD down to <3min

Slide text above is read directly from the Atropos Health deck PDF embedded on this page.

Related fundraising guides (24)

• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Cowboy Pitch Deck Teardown: A Masterclass in High-End Lifestyle Branding and Urban Mobility
• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• IRLY Pitch Deck Teardown: A Gen-Z Dating Playbook Built on Video-First Interaction
• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Anja Health Pitch Deck Teardown: A Narrative-Led Approach to Cord Blood Banking
• Chattermill Pitch Deck Teardown: A Masterclass in Enterprise Social Proof and Expansion Strategy
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• Hintsa Pitch Deck Teardown: A $5.2M Masterclass in High-Performance Wellness Branding
• RegioHelden Pitch Deck Teardown: A Masterclass in Local Marketing Unit Economics
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• Haystack Oncology Pitch Deck Teardown: A Masterclass in Pedigree-Driven Biotech Fundraising
• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round
• Affini-T Therapeutics Pitch Deck Teardown: A $175M Masterclass in Biotech Platform Credibility

Decks from the same year (1)

• 2024 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

More pitch deck teardowns (16)

• Athennian Pitch Deck Breakdown: A Masterclass in Competitive Displacement and Market Timing
• Athina Pitch Deck Teardown: A Pre-Soylent Look at the 'Netflix for Books' Model
• At Home Nursing Services Pitch Deck Teardown: A Healthcare M&A Rollup Strategy
• Athersys Pitch Deck Teardown: A Deep Dive into Clinical-Stage Regenerative Medicine
• ATLAS Pitch Deck Teardown: A Broad Vision for a Crypto-Social 'Super-App'
• AtoB Pitch Deck Breakdown: A Masterclass in Vertical Fintech and Market Expansion
• Atom Limbs Pitch Deck Breakdown: Disrupting Prosthetics with a Hardware-as-a-Service Model
• Atomwise Pitch Deck Breakdown: Building a $5.5B Ecosystem for AI-Driven Medicine
• AT&T × Time Warner Pitch Deck Breakdown: A $106B Vertical Integration Thesis
• Auctio Pitch Deck Breakdown: A Minimalist Approach to B2B Referral Management
• Audience Town Pitch Deck Breakdown: A Vertical AdTech Play for the $1T Real Estate Market
• AudioMob Pitch Deck Breakdown: Solving Mobile Gaming Monetization via Non-Intrusive Audio
• AuditBoard Pitch Deck Breakdown: A $3B Acquisition Masterclass in Enterprise GRC
• Juntoz Pitch Deck Teardown: Scaling a Latin American Online Mall Marketplace
• Audoo Pitch Deck Breakdown: Solving the $2.7 Billion Music Royalty Data Gap
• Teranga Gold Pitch Deck Teardown: A Case Study in Public Market Relative Valuation

Recently published pitch deck teardowns (12)

• Podvertise.fm Pitch Deck Teardown: A Marketplace Play for SMB Podcast Advertising
• Polyflint Pitch Deck Teardown: A Niche Portfolio Play for the 3D Design Economy
• Potential VC Pitch Deck Teardown: A Syndicate-First Approach to Early-Stage UK Investing
• Prolific Pitch Deck Teardown: A Manifesto-Driven Approach to Creative Productivity
• Properati Pitch Deck Teardown: A Performance-Based Play for LatAm Real Estate
• PropMap Pitch Deck Teardown: A Highly Theoretical Approach to Crowdsourced Knowledge Mapping
• Teranga Gold Pitch Deck Teardown: A Masterclass in Public Market Resource Reporting
• Theranos Pitch Deck Teardown: A Case Study in High-Margin Diagnostic Projections
• Codec Pitch Deck Teardown: A Masterclass in High-Signal, Low-Noise Ad Tech Storytelling
• Zoomzin Pitch Deck Teardown: A Granular Look at Early-Stage Loss Prevention Hardware Costs
• PunchUp Pitch Deck Teardown: Leveraging Creator Data to Disintermediate Social Algorithms
• Third Eye Pitch Deck Teardown: A Concept-Stage Vision for Medical Transparency

Fundraising library · Pitch deck examples · Investor directory · Founder database